Annual Report 2006 - Boehringer Ingelheim

only 2 %. The region’s overall net sales reached
EUR 1,379 million, with Japan in the leading
position with a 62 % share of net sales. In 2006,
Japan’s total net sales in PM amounted to EUR
849 million.
Consumer Health Care
In the business segment CHC we increased
our net sales to EUR 1,064 million, a rise of 3 %
compared to the previous year, discounting
currency effects. We continue to pursue our
strategic orientation with a focus on defined key
brands. In 2006, we distinctly strengthened our
presence on the over-the-counter (OTC) market
in the USA by acquiring the product zantac®.
Together with our product dulcolax® we
now have a strong position there in the gastrointestinal
medications segment.
The most important product groups in this
segment in 2006 were:
Net sales
(in millions of EUR) 2006 2005 Growth
dulcolax® 122 115 6 %
mucosolvan® 108 91 19 %
pharmaton® 96 88 9 %
buscopan® 71 59 20 %
Business development was very different from
region to region. While the Americas (+ 10 %)
and Europe (+ 5 %) marked increases in net sales,
turnover in the AAA region (- 9 %) declined. The
reason for the weak development in the AAA
region was the depreciation of the Japanese yen
against the euro.
Industrial Customers
In our Industrial Customers business we have
brought together the third party business of
Pharmaceuticals Production, the Pharma
Chemicals area and our contract manufacturing
of Biopharmaceuticals. Total net sales for these
three business areas in 2006 amounted to EUR
809 million, thereby falling below the figure for
the previous year. It must be noted that the 2005
figures contained favourable, one-off effects in
Biopharmaceuticals. Contract manufacture of
biotechnologically produced medications takes
the most important place.
Animal Health
In the global markets in animal health products,
Boehringer Ingelheim is in No. 10 position, with
a market share of 3 %. Compared to the previous
year, net sales were increased in 2006 by 4 %,
despite the sale in 2005 of some non-strategic
product groups. On the basis of comparable
underlying business, growth in 2006 was 8 %
in local currency terms. Net sales amounted to
EUR 374 million.
Worldwide growth was achieved by the following
product groups in particular:
Net sales
(in millions of EUR) 2006 2005 Growth
enterisol ileitis® 22 17 29 %
vetmedin® 19 16 19 %
metacam® 75 68 10 %
Group Management Report 109